Ruxolitinib Reverses Alopecia Areata Via a Triple Mechanism: JAK-STAT Inhibition, Localized Oxidative Stress Attenuation and Selective Apoptosis Modulation

This study investigates the mechanisms by which ruxolitinib, a JAK inhibitor, reverses alopecia areata (AA) in a C3H/HeJ mouse model. Over 98 days, ruxolitinib treatment led to significant hair regrowth by day 85, reduced inflammatory cytokines, decreased T-cell infiltration, and lowered STAT phosphorylation. It also attenuated local oxidative stress and keratinocyte apoptosis without affecting autophagy or systemic oxidative markers. The study concludes that ruxolitinib's efficacy in treating AA is due to a triple mechanism: inhibition of the JAK-STAT pathway, reduction of local oxidative stress and apoptosis, and disruption of the inflammatory cycle, supporting the potential for targeted topical therapies.